Existing evidence indicates that TP53 mutation is associated with upregulation of immune checkpoints, activation of effector T cells, and increased tumor mutational burden (TMB), whereas KRAS mutation is linked to MAPK-mediated PD-L1 upregulation and neoantigen formation (31–35). This evidence concerns the gene KRAS and neoplasm.